Annual Report

The report describes a pivotal year for Pharming's Ruconest® program: its US Biologics License Application was accepted for FDA review, and the EMA approved an up-scaled manufacturing process. The company also entered a strategic collaboration with SIPI to develop new products using its technology platform. Alongside these milestones, Pharming completed a restructuring to reduce its operating cost base.